参考文献/References:
[1] Yancy CW,Jessup M,Bozkurt B,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J].J Am Coll Cardiol,2013,62(16):e147-e239.
[2] 梁峰,胡大一,方全,等.左室射血分数保留的心力衰竭[J].中国循证心血管医学杂志,2015,7(5):706-709.
[3] Véronique LR. Epidemiology of heart failure[J]. Circ Res,2013,113(6):646-659.
[4] Meta-analysis Global Group in Chronic Heart Failure(MAGGIC).The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient date meta-analysis[J]. Eur Heart J,2012,33(14):1750-1757.
[5] Azad N, Lemay G. Management of chronic heart failure in the older population[J]. J Geriatr Cardiol,2014,11(4):329-337.
[6] Kallikazaros IE. Heart failure with preserved ejection fraction[J]. Hellenic J Cardiol,2014,55:265-266.
[7] Roger VL. Epidemiology of heart failure[J]. Circ Res,2013,113(6):646-659.
[8] Evelien ES, Aron WH, Wagenaar KP,et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time: a systematic review[J]. Eur J Heart Fail,2016,18(3):242-252.
[9] Palmiero P, Zito A, Maiello M,et al.Left ventricular diastolic function in hypertension methodological considerations and clinical implications[J]. J Clin Med Res,2015,7(3):137-144.
[10] Brouwers FP, de Boer RA, van der Harst,et al.Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND[J]. Eur Heart J, 2013,34(19):1424-1431.
[11] Ruijiter D, Pasterkamp G, Rutten FH,et al.Heart failure with preserved ejection fraction in women:the Dutch Queen of Hearts program[J].Neth Heart J,2015,23(2):89-93.
[12] Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment[J]. Eur Heart J,2011,32(6):670-679.
[13] Mohammed SF, Hussain S, Mirzoyev SA. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction[J]. Circulation,2015,131(6):550-559.
[14] Muhammad AH, Mutha V, Rudd N,et al. Heart failure with preserved ejection fraction-unwinding the diagnosis mystique[J]. Am J Cardiovasc Dis,2014,4(3):100-113.
[15] Chinese Society of Cardiology of Chinese Medical Association, Chinese Journal of Cardiology editorial board. Guidelines for diagnosis and treatment of heart failure in China(2014)[J].Chin J Cardiol,2014,42(2):98-122.
[16] Sakata Y, Ohtani T, Takeda Y,et al. Left ventricular stiffening as therapeutic target for heart failure with preserved ejection fraction[J]. Circ J,2013,77(4):886-892.
[17] Flachskampf FA, Biering-S?rensen T, Solomon SD, et al. Cardiac imaging to evaluate left ventricular diastolic function[J]. JACC Cardiovasc Imaging, 2015,8(9):1071-1093.
[18] Collerton J, Kingston A, Yousaf F,et al.Utility of NT-proBNP as a rule-out test for left ventricular dysfunction in very old people with limiting dyspnoea:the Newcastle 85+ Study[J]. BMC Cardiovasc Disord,2014,14:128-140.
[19] Tate S, Griema A, Durbin-Johnson B,et al. Marked elevation of B-type natriuretic peptide in patients with heart failure and preserved ejection fraction[J]. J Biomed Res,2014,28(4):255-261.
[20] Muhammad AH, Wong C, Mutha V,et al. Therapeutic interventions for heart failure with preserved ejection fraction:a summary of current evidence[J]. World J Cardiol,2014,6(2):67-76.
[21] Li Jia, Becher PM, Blankenberg S,et al. Current treatment of heart failure with preserved ejection fraction: should we add life to the remaining years or add years to the remaining life?[J]. Cardiol Res Pract,2013,2013:130724.
[22] Cleland JGF, Tendera M, Adamus J,et al.The perindopril in elderly people with chronic heart failure(PEP-CHF)study[J]. Eur Heart J,2006,27(19):2338-2345.
[23] Kao DP, Lewsey JD, Anand IS,et al.Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response[J]. Eur J Heart Fail,2015,17(9):925-935.
[24] Owens AT, Brozena SC, Jessup M. New management strategies in heart failure[J]. Circ Res,2016,118(3):480-495.
[25] Liu F, Chen Y, Feng XG,et al.Effects of beta-blockers on heart failure with preserved ejection fraction:a meta-analysis[J]. PLoS One,2014,9(3):e90555.
[26] Elguindy AM. TOPCAT Misses its primary endpoint: should spironolactone be abandoned in HFpEF?[J]. Glob Cardiol Sci Pract,2013,42(10):357-360.
[27] Shah SJ, Heitner JF, Sweitzer NK,et al.Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial[J]. Circ Heart Fail,2013,6(2):184-192.
[28] Kitzman DW, Brubaker PH, Herrington DM,et al.Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial[J]. J Am Coll Cardiol,2013,62(7):584-592.
[29] Jackson CE, Castagno D, Maggioni A,et al.Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction:results from the MAGGIC individual patient meta-analysis[J]. Eur Heart J,2015,36(18):1106-1114.
[30] Vaduganathan M, Fonarow GC.Epidemiology of hospitalized heart failure:differences and similarities between patients with reduced versus preserved ejection fraction[J]. Heart Fail Clin,2013,9(3):271-276.
[31] Becher PM, Fluschnik N, Blankenberg S,et al.Challenging aspects of treatment strategies in heart failure with preserved ejection fraction:”Why did recent clinical trials fail?”[J]. World J Cardiol,2015,7(9): 544-554.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(4):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(4):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(4):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[5]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(4):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[6]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(4):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[7]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(4):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[8]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(4):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[9]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(4):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
[10]方砚 王效浣 郭朝霞.血流介导性血管扩张评价心血管病患者肱动脉内皮功能的研究进展[J].心血管病学进展,2019,(5):793.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.032]
FANG Yan,WANG Xiaohuan,GUO Zhaoxia.Flow- mediated Vasodilation Evaluation of Brachial Artery Endothelial Function in Patients with Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(4):793.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.032]